<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-297" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antiplatelet Drug Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pirozzi</surname>
            <given-names>Elisa J.</given-names>
          </name>
          <aff>Trinity College Dublin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wills</surname>
            <given-names>Brandon K.</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elisa Pirozzi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brandon Wills declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-297.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antiplatelet medications are primarily used for the management and prevention of cardiovascular disease (CVD) related events. Currently, there are four classifications of these agents based upon the mechanism of action utilized, but all inhibit platelet activation and aggregation ultimately. This activity reviews the indications and actions of these medications, as well as the treatment of toxic exposure to them. The toxicokinetics, adverse event profile, and specific management of these agents will be highlighted for the edification of the interprofessional healthcare team when employing antiplatelet therapy to patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of antiplatelet toxicity.</p></list-item><list-item><p>Outline the typical presentation of a patient with antiplatelet toxicity.</p></list-item><list-item><p>Summarize the recommended management of the main adverse event associated with antiplatelet toxicity.</p></list-item><list-item><p>Explain the importance of collaboration and communication among the interprofessional team members to improve the delivery of care for patients receiving antiplatelet therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=297&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=297">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-297.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>As the prevalence of cardiovascular disease (CVD) escalates worldwide, so does the use of antiplatelet medications in its management.<xref ref-type="bibr" rid="article-297.r1">[1]</xref> These agents are used to decrease major adverse events due to acute coronary syndromes, peripheral vascular disease, and stroke.<xref ref-type="bibr" rid="article-297.r2">[2]</xref> Despite a variety of pharmacologic actions, all antiplatelet drugs inhibit platelet activation and aggregation, lowering atherothrombotic related events.<xref ref-type="bibr" rid="article-297.r1">[1]</xref><xref ref-type="bibr" rid="article-297.r3">[3]</xref> Given the relatively narrow pharmacologic actions of antiplatelet drugs, toxicity primarily confines itself to an increased risk of hemorrhage. When compared to individuals not taking antiplatelet medications, patients on an antiplatelet agent have a 1.5 times greater risk of bleeding, and this increases when taking additional antiplatelet agents.<xref ref-type="bibr" rid="article-297.r2">[2]</xref> The toxicity of salicylates is complex. As such, a separate monograph specifically devoted to salicylate toxicity is available.<xref ref-type="bibr" rid="article-297.r4">[4]</xref> Salicylates are only briefly mentioned here, primarily in comparing various mechanisms of antiplatelet drugs.</p>
      </sec>
      <sec id="article-297.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Antiplatelet drug toxicity can be the result of either therapeutic dosing or overdose. Adverse drug effects from therapeutic dosing or overdose can result in hemorrhage. A summary of 2017 National Poison Center data reported 2,831 cases of antiplatelet drug exposures with 972 being unintentional and 48 intentional.<xref ref-type="bibr" rid="article-297.r5">[5]</xref>&#x000a0;With an overdose of antiplatelet drugs, there are no other significant organ system effects that are impacted but an exaggerated antiplatelet effect may cause a variety of bleeding disorders.</p>
      </sec>
      <sec id="article-297.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There were 2831 cases of antiplatelet exposures reported to United States poison centers in 2017. The majority of exposures were unintentional and occurred in individuals less than 20 years of age. Of these cases, 198 sought care in a medical facility, with 16 moderate outcomes, five major outcomes, and no deaths reported.<xref ref-type="bibr" rid="article-297.r5">[5]</xref> An overdose of antiplatelet medications increases the risk of significant hemorrhage, although the risk is lower than for anticoagulants.<xref ref-type="bibr" rid="article-297.r6">[6]</xref></p>
      </sec>
      <sec id="article-297.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Under physiological conditions, platelets are activated by a series of intracellular signals when vascular endothelium is damaged. Underlying collagen interacts with tissue factor (TF) to trigger the clotting cascade, activating thrombin, which contributes to platelet adhesion at the injury site. Simultaneously, collagen also binds von Willebrand factor (vWF) to activate platelets via glycoprotein (GP) Ia/IIa and GP IV receptors. Mediators including thromboxane A2, adenosine diphosphate (ADP), thromboxane A2 (TXA2), and cAMP activate platelets, and activation of GPIIb/IIIa receptors promote platelet aggregation.<xref ref-type="bibr" rid="article-297.r1">[1]</xref> While the final common pathway is platelet inhibition, there are several different mechanisms that antiplatelet agents can utilize.</p>
        <p>The most widely used antiplatelet drugs are cyclooxygenase (COX) inhibitors, such as aspirin. This class irreversibly inhibits COX-1 preventing TXA2, which is essential for platelet aggregation.<xref ref-type="bibr" rid="article-297.r3">[3]</xref> Oral low dose aspirin is given preventatively for ischemic stroke and cardiovascular events.<xref ref-type="bibr" rid="article-297.r7">[7]</xref></p>
        <p>Clopidogrel and prasugrel are prodrugs that irreversibly block P2Y12 receptors on platelets after undergoing conversion to their respective active metabolites.<xref ref-type="bibr" rid="article-297.r3">[3]</xref> Ticagrelor directly but reversibly binds the P2Y12 receptor.<xref ref-type="bibr" rid="article-297.r8">[8]</xref> By both mechanisms, ADP-mediated aggregation becomes inhibited.<xref ref-type="bibr" rid="article-297.r3">[3]</xref></p>
        <p>Abciximab and eptifibatide are GP IIb/IIIa inhibitors that elicit their effects by blocking the GPIIb/IIIa receptors on the platelet surface to prevent aggregation.<xref ref-type="bibr" rid="article-297.r3">[3]</xref></p>
        <p>Phosphodiesterase inhibitors such as cilostazol and dipyridamole exert their antiplatelet effects by increasing cAMP levels in platelets. As cAMP levels rise inside the platelets, TXA2 levels decrease, effectively hindering aggregation abilities.<xref ref-type="bibr" rid="article-297.r3">[3]</xref><xref ref-type="bibr" rid="article-297.r7">[7]</xref>&#x000a0;Dipyridamole is also thought to inhibit the reuptake of adenosine, which would amplify the effect on cAMP levels.<xref ref-type="bibr" rid="article-297.r2">[2]</xref></p>
      </sec>
      <sec id="article-297.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Detailed information on the toxicokinetics for these agents is limited. Detailed pharmacokinetics for aspirin is covered in the salicylate chapter. Briefly, gastrointestinal aspirin absorption is variable and depends on the dose, tablet formulation, and rate of gastric emptying.<xref ref-type="bibr" rid="article-297.r9">[9]</xref> Aspirin gets hydrolyzed into salicylic acid utilizing two hepatic pathways: glucuronide formation and conjugation with glycine.<xref ref-type="bibr" rid="article-297.r10">[10]</xref> Salicylic acid&#x02019;s serum half-life is directly proportional to dosing.<xref ref-type="bibr" rid="article-297.r10">[10]</xref>&#x000a0; Aspirin is renally eliminated and follows mixed elimination kinetics depending on the salicylate concentration. Other factors influencing elimination are urine pH, presence of organic acids, and urine flow rate.<xref ref-type="bibr" rid="article-297.r10">[10]</xref></p>
        <p>The P2Y12 receptor inhibitors, (clopidogrel, prasugrel, and ticagrelor), are rapidly absorbed by the gastrointestinal tract with a bioavailability of approximately 50%, 79%, 78% respectively.<xref ref-type="bibr" rid="article-297.r11">[11]</xref><xref ref-type="bibr" rid="article-297.r12">[12]</xref> Prasugrel&#x02019;s absorption gets delayed when taken with food.<xref ref-type="bibr" rid="article-297.r12">[12]</xref>&#x000a0;All three agents are 98% to 99% protein-bound and have a large volume of distribution.<xref ref-type="bibr" rid="article-297.r8">[8]</xref><xref ref-type="bibr" rid="article-297.r12">[12]</xref>&#x000a0; The P2Y12 receptor inhibitors undergo hepatic metabolization by the CYP enzymes.<xref ref-type="bibr" rid="article-297.r11">[11]</xref><xref ref-type="bibr" rid="article-297.r12">[12]</xref><xref ref-type="bibr" rid="article-297.r13">[13]</xref>&#x000a0;Clopidogrel is a prodrug metabolized by CYP2B6, CYP2C19, CYP3A4, and CYP3A5 into its active thiol metabolite.<xref ref-type="bibr" rid="article-297.r11">[11]</xref><xref ref-type="bibr" rid="article-297.r14">[14]</xref>&#x000a0;Prasugrel is also a prodrug, metabolized by CYP3A4 and CYP2B6 to form its active metabolite.<xref ref-type="bibr" rid="article-297.r12">[12]</xref> Final clearance of clopidogrel and prasugrel occurs via renal and fecal elimination.<xref ref-type="bibr" rid="article-297.r11">[11]</xref><xref ref-type="bibr" rid="article-297.r12">[12]</xref> Ticagrelor gets eliminated by biliary excretion.<xref ref-type="bibr" rid="article-297.r8">[8]</xref></p>
        <p>Orally dosed dipyridamole has variable absorption&#x000a0;and is 99% protein bound with a half-life of approximately 12 hours.<xref ref-type="bibr" rid="article-297.r15">[15]</xref><xref ref-type="bibr" rid="article-297.r16">[16]</xref>&#x000a0;It converts to the monoglucuronide form by hepatic biotransformation and gets cleared by biliary and fecal excretion.<xref ref-type="bibr" rid="article-297.r15">[15]</xref></p>
        <p>Cilostazol also has decreased absorption when administered orally; however, the reason for these low rates stems from its limited solubility.<xref ref-type="bibr" rid="article-297.r17">[17]</xref> Its extensive distribution and low first-pass metabolism are indicated by low plasma clearance and high Vd (volume of distribution) values.<xref ref-type="bibr" rid="article-297.r17">[17]</xref> Analogous to the antiplatelet medications discussed previously, cilostazol also undergoes hepatic metabolization via CYP enzymes into two main metabolites: 3,4-dehydrocilostazol and 4'-trans-hydroxycilostazol.<xref ref-type="bibr" rid="article-297.r14">[14]</xref> Considering no unchanged drug is detected in urine, the elimination of cilostazol is thought to be almost entirely metabolism-based.<xref ref-type="bibr" rid="article-297.r17">[17]</xref></p>
        <p>Abciximab and eptifibatide are parenteral antiplatelet drugs with very low volumes of distribution.<xref ref-type="bibr" rid="article-297.r18">[18]</xref> Abciximab has a plasma half-life of 20 minutes. However, antiplatelet effects can persist up to 48 hours after drug cessation.<xref ref-type="bibr" rid="article-297.r19">[19]</xref> Eptifibatide has a plasma half-life of two hours, but the duration of antiplatelet effects is similar to abciximab. Eptifibatide undergoes mostly renal clearance.<xref ref-type="bibr" rid="article-297.r18">[18]</xref></p>
      </sec>
      <sec id="article-297.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>For any suspected antiplatelet toxicity, thorough exposure history and physical exam will aid decision-making for subsequent laboratory investigations and treatment.<xref ref-type="bibr" rid="article-297.r20">[20]</xref> Focused questions may include how much medication the patient took, route of administration, co-ingestants, and intent. Since hemorrhage is of primary concern in antiplatelet toxicity, a review of systems focusing on bleeding presentations is reasonable. The history should also include a medication review to determine any potential interactions or synergy that may compound the bleeding risk with antiplatelet drugs. If overt bleeding is present, further characterization should be done by determining the onset, duration, and location.<xref ref-type="bibr" rid="article-297.r20">[20]</xref> Furthermore, a clinical assessment for these patients should include vital signs and identification of any platelet dysfunction manifestations such as subconjunctival hemorrhage, ecchymosis, petechiae, epistaxis, gingival bleeding, hematuria, or gastrointestinal bleeding.<xref ref-type="bibr" rid="article-297.r20">[20]</xref> An abnormal neurologic exam may be an indication of intracranial hemorrhage.</p>
      </sec>
      <sec id="article-297.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Monitoring platelet function for therapeutic monitoring of an antiplatelet regimen or after an overdose is difficult. Bleeding time reflects platelet function but has significant limitations.<xref ref-type="bibr" rid="article-297.r21">[21]</xref> A newer assay, light transmittance aggregometry, is not widely available and also has disadvantages.<xref ref-type="bibr" rid="article-297.r21">[21]</xref> Thromboelastography (TEG), an increasingly popular assay of global hemostatic function, has conflicting data on the utility of TEG in patients on antiplatelet drugs.<xref ref-type="bibr" rid="article-297.r22">[22]</xref><xref ref-type="bibr" rid="article-297.r23">[23]</xref></p>
        <p>For patients presenting with bleeding, laboratory studies can include a complete blood count for determining both platelet count and total hemoglobin.<xref ref-type="bibr" rid="article-297.r20">[20]</xref> Bleeding time and platelet function analysis (PFA-100) will highlight functional abnormalities while a peripheral blood smear identifies any morphological abnormalities.<xref ref-type="bibr" rid="article-297.r20">[20]</xref> Additional tests that may be useful in the setting of serious hemorrhage include prothrombin time (PT), activated partial thrombin time (APTT), and cross-match of packed red blood cells.</p>
      </sec>
      <sec id="article-297.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Currently, there no specific antidotes for any antiplatelet medications discussed above, and reversal guidelines are not universal. Activated charcoal can be considered if the patient can safely take oral liquids, and the patient arrives early post-ingestion, typically within the first 1 to 2 hours. Initial treatment should focus on local hemorrhage control. Gastrointestinal hemorrhage, if proximal or distal, may be amenable to endoscopic evaluation and treatment. Management for patients presenting with severe bleeding associated with antiplatelet medications may&#x000a0;include platelet transfusions and desmopressin. However, there is no robust data to support desmopressin.<xref ref-type="bibr" rid="article-297.r2">[2]</xref><xref ref-type="bibr" rid="article-297.r7">[7]</xref>&#x000a0;Desmopressin exerts its effect by increasing levels of factor VIII and Von Willebrand factor to induce platelet aggregation via GPllb/IIIa, interactions that are mechanistically distinct from antiplatelet drugs.<xref ref-type="bibr" rid="article-297.r2">[2]</xref> Resuscitation with blood products, including packed red blood cells and platelets may be necessary for severe hemorrhage. If there is associated coagulopathy from severe hemorrhage, plasma may also be required. For GPIIb/IIIa inhibitors, discontinuation of infusion will result in normalization of platelet function within 48 to 72 hours for abciximab and 4 to 8 hours for eptifibatide and tirofiban.<xref ref-type="bibr" rid="article-297.r7">[7]</xref></p>
      </sec>
      <sec id="article-297.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The clinical presentation for patients on antiplatelet therapy will be bleeding complications. The differential diagnosis will differ depending on the source of bleeding. Gastrointestinal, genitourinary, intracranial, or other types of bleeding will each have distinct differential diagnoses. It is reasonable, therefore, to consider antiplatelet drug toxicity and perform medication reconciliation for all patients presenting with bleeding-related complaints.</p>
      </sec>
      <sec id="article-297.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis will vary depending on the location and severity of the bleeding. The natural history of antithrombotic exposure is generally benign. Nevertheless, serious bleeding complications and death can occur. National Poison Data System data from 2017 revealed five major outcomes and zero deaths from 2831 exposures.<xref ref-type="bibr" rid="article-297.r5">[5]</xref>&#x000a0;Another poison center study of antiplatelet overdoses reported 322 acute overdoses with 16 cases of hemorrhage that included two deaths.<xref ref-type="bibr" rid="article-297.r6">[6]</xref>&#x000a0;Patients suffering from an intracranial hemorrhage while on antiplatelet or anticoagulant medications have significantly worse outcomes than those who are not.<xref ref-type="bibr" rid="article-297.r24">[24]</xref></p>
      </sec>
      <sec id="article-297.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Hemorrhagic complications could include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intracranial hemorrhage</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal hemorrhage</p>
          </list-item>
          <list-item>
            <p>Retroperitoneal bleeding</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic shock</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-297.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The clinician or patient can obtain a consultation with a medical toxicologist and/or regional poison center in the United States by calling (800) 222-1222.</p>
      </sec>
      <sec id="article-297.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients that are prescribed antiplatelet medications should be educated on the risk of bleeding related to these medications. They should also be encouraged to keep these medications in a safe place where young children cannot access them. Patients on these medications are encouraged to call their regional poison center should they have questions or concerns regarding possible toxicity.</p>
      </sec>
      <sec id="article-297.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As the population continues to age, there will likely be an increasing prevalence of antiplatelet drug use. Most exposures will not have severe symptoms and not require a lot of healthcare resources. Others can have devastating complications requiring interprofessional care. Additionally, the healthcare team should ascertain whether the exposure was intentional or unintentional, which may lead to involvement in mental health services.&#x000a0;</p>
        <p>The majority of patients will present with bleeding ranging from mild to severe, and clinicians in the emergency department need to be aware that there is no specific antidote to any of these agents. Thus, supportive care is necessary. The clinician should consult with a hematologist and poison control on the management of patients with moderate to severe bleeding. Some patients may need to be admitted and managed with transfusion of blood products. The pharmacist should thoroughly educate patients about the adverse effect profile and when to seek medical help. Prevention of and early intervention in cases of antiplatelet agent toxicity are crucial. The pharmacist can play a critical role by monitoring doses and verifying that there are no drug-drug interactions that can enhance antiplatelet activity beyond the therapeutic level. Nursing will help assess therapy effectiveness and watch for adverse events; they may be the first to have the opportunity to notice something is amiss. Specialty trained nurses in emergency medicine and critical care will be responsible for monitoring patients. Cardiovascular specialty nurses play a role in patient education of the patient and family. In both instances, immediate consultation with the managing clinician is important to make necessary changes to the treatment regimen or initiate other interventions.</p>
        <p>The interprofessional team should communicate with other members if there is a dose change/frequency of use of the antiplatelet medication. Only through open communication can the morbidity of these agents be reduced. [Level 5]</p>
      </sec>
      <sec id="article-297.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=297&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=297">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/antiplatelet-drug-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=297">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/297/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=297">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-297.s17">
        <title>References</title>
        <ref id="article-297.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Habtewold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burmeister</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Risk Reduction: A Pharmacotherapeutic Update for Antiplatelet Medications.</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-30</page-range>
            <pub-id pub-id-type="pmid">30736932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raimondi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Aronis</surname>
                <given-names>KN</given-names>
              </name>
            </person-group>
            <article-title>Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.</article-title>
            <source>Curr Pharm Des</source>
            <year>2017</year>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1406</fpage>
            <page-range>1406-1423</page-range>
            <pub-id pub-id-type="pmid">27917717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Iqbal</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hai</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <chapter-title>Antiplatelet Medications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30725747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Runde</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <chapter-title>Salicylates Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29763054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Osterthaler</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>12</issue>
            <fpage>1213</fpage>
            <page-range>1213-1415</page-range>
            <pub-id pub-id-type="pmid">30576252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pizon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cantrel</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Spyres</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>LoVecchio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Assessing Bleeding Risk in Patients With Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications.</article-title>
            <source>Ann Emerg Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-278</page-range>
            <pub-id pub-id-type="pmid">29032872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dornbos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nimjee</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics.</article-title>
            <source>Neurosurg Clin N Am</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-545</page-range>
            <pub-id pub-id-type="pmid">30223966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2010</year>
            <month>May</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>487</fpage>
            <page-range>487-96</page-range>
            <pub-id pub-id-type="pmid">20091161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of aspirin.</article-title>
            <source>Pediatrics</source>
            <year>1978</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>5 Pt 2 Suppl</issue>
            <fpage>867</fpage>
            <page-range>867-72</page-range>
            <pub-id pub-id-type="pmid">724339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Needs</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of the salicylates.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1985</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-77</page-range>
            <pub-id pub-id-type="pmid">3888490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tanguay</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Joyner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Rupprecht</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bassand</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Pasquale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Niemela</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ajani</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <collab>CURRENT-OASIS 7 trial investigators</collab>
            </person-group>
            <article-title>Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Oct</month>
            <day>09</day>
            <volume>376</volume>
            <issue>9748</issue>
            <fpage>1233</fpage>
            <page-range>1233-43</page-range>
            <pub-id pub-id-type="pmid">20817281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maya</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers.</article-title>
            <source>J Drug Assess</source>
            <year>2014</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-50</page-range>
            <pub-id pub-id-type="pmid">27536453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XP</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2017</year>
            <month>Mar</month>
            <day>14</day>
            <volume>14</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28335443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghim</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-12</page-range>
            <pub-id pub-id-type="pmid">26426352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen-Kudsk</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of dipyridamole.</article-title>
            <source>Acta Pharmacol Toxicol (Copenh)</source>
            <year>1979</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>391</fpage>
            <page-range>391-9</page-range>
            <pub-id pub-id-type="pmid">474151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjornsson</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Mahony</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of dipyridamole.</article-title>
            <source>Thromb Res Suppl</source>
            <year>1983</year>
            <volume>4</volume>
            <fpage>93</fpage>
            <page-range>93-104</page-range>
            <pub-id pub-id-type="pmid">6579711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Mallikaarjun</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1999</year>
            <volume>37 Suppl 2</volume>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">10702882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schr&#x000f6;r</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Comparative pharmacology of GP IIb/IIIa antagonists.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-80</page-range>
            <pub-id pub-id-type="pmid">14618072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sukul</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hanzel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lalonde</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Gurm</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).</article-title>
            <source>J Interv Cardiol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-300</page-range>
            <pub-id pub-id-type="pmid">28543770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bashawri</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The approach to a patient with a bleeding disorder: for the primary care physician.</article-title>
            <source>J Family Community Med</source>
            <year>2007</year>
            <month>May</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">23012146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orme</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Monitoring Antiplatelet Therapy.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-319</page-range>
            <pub-id pub-id-type="pmid">28264200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative and postoperative effects of TEG-guided platelet transfusion on antiplatelet drug-related intracerebral hemorrhage patients.</article-title>
            <source>Exp Ther Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>2263</fpage>
            <page-range>2263-2267</page-range>
            <pub-id pub-id-type="pmid">30783485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katyal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Natteru</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nattanamai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Newey</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Thromboelastography With Platelet Mapping is Not an Effective Measure of Platelet Inhibition in Patients With Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Apr</month>
            <day>22</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e2515</fpage>
            <pub-id pub-id-type="pmid">29942718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-297.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romem</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tanne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Geva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Einhorn-Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shlomo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bar-Yehuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harnof</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antithrombotic Treatment Prior to Intracerebral Hemorrhage: Analysis in the National Acute Stroke Israeli Registry.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>3380</fpage>
            <page-range>3380-3386</page-range>
            <pub-id pub-id-type="pmid">30205997</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
